Andreas Hallqvist1, Charlotte Alverbratt2, Annika Strandell3, Ola Samuelsson3, Emil Björkander4, Ann Liljegren4, Per Albertsson2. 1. Department of Oncology, Sahlgrenska University Hospital, Göteborg, Sweden. Electronic address: andreas.hallqvist@oncology.gu.se. 2. Department of Oncology, Sahlgrenska University Hospital, Göteborg, Sweden. 3. HTA-centrum of Region Västra Götaland, Sweden. 4. Medical Library, Sahlgrenska University Hospital, Göteborg, Sweden.
Abstract
BACKGROUND AND PURPOSE: PET/CT is a proposed management to improve the accuracy of high dose radiochemotherapy in lung cancer patients. This systematic review was performed to investigate the possible impact on clinical outcome and to quantify the effect on patient selection and target definition. MATERIAL AND METHODS: Systematic literature searches were conducted, eligible full-text articles were assessed for quality and data were extracted. RESULTS: Thirty-five cross-sectional studies and one observational study fulfilled the inclusion criteria. No randomized trials or data with regard to clinical endpoints were found. The summary estimates of a change in target definition were 36% in patients with a former staging PET, and 43% and 26% in patients without a staging PET, for non small- and small cell lung cancer respectively. The corresponding summary estimates of a change in treatment intent from curative to palliative treatment were 20% and 22% and 9% respectively. CONCLUSION: PET/CT for dose planning improves target definition and patient selection. Approximately two in five patients had a significant change in target definition and one in five received palliative treatment instead. The proportions seem to be similar regardless of the availability of a previous staging-PET.
BACKGROUND AND PURPOSE: PET/CT is a proposed management to improve the accuracy of high dose radiochemotherapy in lung cancerpatients. This systematic review was performed to investigate the possible impact on clinical outcome and to quantify the effect on patient selection and target definition. MATERIAL AND METHODS: Systematic literature searches were conducted, eligible full-text articles were assessed for quality and data were extracted. RESULTS: Thirty-five cross-sectional studies and one observational study fulfilled the inclusion criteria. No randomized trials or data with regard to clinical endpoints were found. The summary estimates of a change in target definition were 36% in patients with a former staging PET, and 43% and 26% in patients without a staging PET, for non small- and small cell lung cancer respectively. The corresponding summary estimates of a change in treatment intent from curative to palliative treatment were 20% and 22% and 9% respectively. CONCLUSION: PET/CT for dose planning improves target definition and patient selection. Approximately two in five patients had a significant change in target definition and one in five received palliative treatment instead. The proportions seem to be similar regardless of the availability of a previous staging-PET.
Authors: Robert H Press; Hui-Kuo G Shu; Hyunsuk Shim; James M Mountz; Brenda F Kurland; Richard L Wahl; Ella F Jones; Nola M Hylton; Elizabeth R Gerstner; Robert J Nordstrom; Lori Henderson; Karen A Kurdziel; Bhadrasain Vikram; Michael A Jacobs; Matthias Holdhoff; Edward Taylor; David A Jaffray; Lawrence H Schwartz; David A Mankoff; Paul E Kinahan; Hannah M Linden; Philippe Lambin; Thomas J Dilling; Daniel L Rubin; Lubomir Hadjiiski; John M Buatti Journal: Int J Radiat Oncol Biol Phys Date: 2018-06-30 Impact factor: 7.038
Authors: M Unterrainer; C Eze; H Ilhan; S Marschner; O Roengvoraphoj; N S Schmidt-Hegemann; F Walter; W G Kunz; P Munck Af Rosenschöld; R Jeraj; N L Albert; A L Grosu; M Niyazi; P Bartenstein; C Belka Journal: Radiat Oncol Date: 2020-04-21 Impact factor: 3.481
Authors: Matthias Mäurer; Lukas Käsmann; Daniel F Fleischmann; Michael Oertel; Danny Jazmati; Daniel Medenwald Journal: Radiat Oncol Date: 2022-02-09 Impact factor: 3.481
Authors: Sofia C Vaz; Judit A Adam; Roberto C Delgado Bolton; Pierre Vera; Wouter van Elmpt; Ken Herrmann; Rodney J Hicks; Yolande Lievens; Andrea Santos; Heiko Schöder; Bernard Dubray; Dimitris Visvikis; Esther G C Troost; Lioe-Fee de Geus-Oei Journal: Eur J Nucl Med Mol Imaging Date: 2022-01-13 Impact factor: 10.057
Authors: Sofia C Vaz; Judit A Adam; Roberto C Delgado Bolton; Pierre Vera; Wouter van Elmpt; Ken Herrmann; Rodney J Hicks; Yolande Lievens; Andrea Santos; Heiko Schöder; Bernard Dubray; Dimitris Visvikis; Esther G C Troost; Lioe-Fee de Geus-Oei Journal: Radiother Oncol Date: 2022-01-20 Impact factor: 6.901